Augurex - Personalized Medicine Drug Target Extracellular - Arthritis
In the development of RA and other inflammatory types of arthritis, multiple factors contribute to disease processes to varying degrees in different patients. 14-3-3η is recognized as a new factor within this process and represents a rationale drug target for personalized medicine alongside its 14-3-3η companion biomarker portfolio described above. Augurex preclinical animal studies to date demonstrate that anti-14-3-3η monoclonal antibodies delay the onset of and mitigate the severity of arthritis development. This continued research has the potential to produce the first true personalized medicine in RA, wherein patients with varying levels of 14-3-3η measured by the companion biomarkers, can be optimally dosed with the anti-14-3-3η therapy and monitored for clearance of the protein and maintenance of negative levels along the disease course.
Product Details
- 14-3-3η is a Novel Mediator Associated with the Pathogenesis of Rheumatoid Arthritis and Joint Damage
- Review: 14-3-3η – a Novel Biomarker Platform for Rheumatoid Arthritis
- Serum 14-3-3η is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis
- 14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis
- The Diagnostic Value of 14-3-3η Protein Levels in Patients with Rheumatoid Arthritis
- Serum 14-3-3η Protein is Associated with Clinical and Serologic Features of Sjögren’s Syndrome in Patients with Systemic Lupus Erythematosus: A Cross-Sectional Analysis
- Serum Levels of 14-3-3η Protein Supplement C-reactive Protein and Rheumatoid Arthritis-Associated Antibodies to Predict Clinical and Radiographic Outcomes in a Prospective Cohort of Patients with Recent-Onset Inflammatory Polyarthritis
- Impending Radiographic Erosive Progression Over the Following Year in a Cohort of Consecutive Patients with Inflammatory Polyarthritis: Prediction by Serum Biomarkers
Monitoring
- Serum 14-3-3η Level is Associated with Severity and Clinical Outcomes of Rheumatoid Arthritis, and its Pretreatment Level is Predictive of DAS28 Remission with Tocilizumab
- Decrease in 14-3-3η Protein Levels is Correlated with Improvement in Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib
- Correlation of Plasma 14-3-3η Levels with Disease Activity Measures in Methotrexate-Naïve RA Patients Treated with Upadacitinib Monotherapy in the Select-Early Phase 3 Study
Customer reviews
No reviews were found for Augurex - Personalized Medicine Drug Target Extracellular - Arthritis. Be the first to review!